• DEGRADATION OF EGFR CONTRIBUTES TO ANTI-CANCER EFFECTS OF HDAC INHIBITOR IN HEAD AND NECK CANCER

      Duncan, Leslie; Jensen, Caleb; He, Leilei; Lang, Liwei; Teng, Yong; Biological Sciences; Oral Biology and Diagnostic Sciences; Georgia Cancer Center; Teng, Yong; Lang, Liwei; et al. (1/16/2020)
      A promising arsenal of histone deacetylase (HDAC)-targeted treatment has emerged in the past decade, as the abnormal targeting or retention of HDACs to DNA regulatory regions often occurs in many cancers, including head and neck squamous cell carcinoma (HNSCC). However, few has been studied regarding the beneficial role of HDAC inhibition in anti-HNSCC therapy and the underlying molecular mechanisms remain elusive. Epidermal growth factor receptor (EGFR) is commonly expressed at high levels in HNSCC (more than 90%) and serves as a prime target for new anti-HNSCC therapy. Interestingly, Trichostatin A (TSA), one of HDAC inhibitors, not only inhibits EGFR phosphorylation, but also induces repression of EGFR total protein amount in HNSCC cells. We further show that TSA induces EGFR degradation through the ubiquitin-proteasome pathway in HNSCC cells, which is associated with downregulated AKT and ERK1/2 signaling pathways. The study uncovers that EGFR is one of targets of HDAC-based treatment, providing mechanistic insight into the action of HDAC inhibitors. As there is an increasing interest in using HDAC inhibitors for cancer treatment in the clinic, the outcomes from the present study would be significantly beneficial for the development of new rational HDAC-targeted anticancer modalities.